Not negative spin and it's positive news, but company is right to say small market, GLOBOCAN shows 855 new pancreatic cancer cases in 2018 in Singapore. Expect around 30% of those to be eligible for device (locally advanced stage), under 300 per year. Some things aren't clear to me from this ANN is whether any further steps to sell device (reimbursement?) also has there been any previous experience using the device in pancreatic cancer patients in any Singapore hospital? Does OSL have any staff in Singapore to manage training hospitals? Will the device fit with medical practice in Singapore?
Singapore I thought was getting a bit of a second wave of covid19, are there any restrictive measures still around that could delay launch of device there?
Not negative spin and it's positive news, but company is right...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $52.97M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.4¢ | 1.3¢ | $56.50K | 4.041M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 12011630 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 6141425 | 9 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| OSL (ASX) Chart |